Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients
Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients
复制标题
DOI：
10.1007/s00380-010-0060-x
复制
发表时间：
2011-07-01
影响因子：
1.5
通讯作者：
Kusachi, Shozo
中科院分区：
文献类型：
--
作者：
Miyoshi, Toru;Doi, Masayuki;Kusachi, Shozo
脂肪细胞脂肪酸结合蛋白（A-FABP）已被报道参与胰岛素抵抗、脂质代谢和动脉粥样硬化;然而，关于药物对人类受试者中循环A-FABP变化的影响知之甚少。我们评估了血管紧张素II 1型受体阻滞剂（ARB）对高血压患者动脉僵硬度的影响及其与血清A-FABP的相关性。30例新诊断的原发性高血压患者接受奥美沙坦（20 mg/d）（一种ARB）治疗6个月。检测血清A-FABP和高敏C反应蛋白（hsCRP）水平，并测定心踝血管指数（CAVI），这是动脉僵硬度的标志物。基线时血清A-FABP与体重指数（r = 0.45，P = 0.01）、作为胰岛素抵抗标志物的稳态模型评估（r = 0.53，P < 0.01）和收缩压（r = 0.37，P = 0.047）显著相关，并倾向于与低密度脂蛋白胆固醇、甘油三酯和CAVI相关。奥美沙坦治疗导致CAVI、血清A-FABP水平和hsCRP显著降低，血压显著降低。多元回归分析显示CAVI的变化与血清A-FABP的变化独立相关。奥美沙坦可改善高血压患者的动脉僵硬度，其机制可能与降低血清A-FABP有关。
Adipocyte fatty acid binding protein (A-FABP) has been reported to be involved in insulin resistance, lipid metabolism, and atherosclerosis; however, little is known about the effect of medication on the change in circulating A-FABP in human subjects. We evaluated the effects of angiotensin II type 1 receptor blocker (ARB) on arterial stiffness and its association with serum A-FABP in patients with hypertension. Thirty patients newly diagnosed with essential hypertension were treated with olmesartan (20 mg/day), an ARB, for 6 months. Serum levels of A-FABP and high-sensitivity C-reactive protein (hsCRP) were examined and the cardio-ankle vascular index (CAVI), which is a marker of arterial stiffness, was also determined. Serum A-FABP at baseline was significantly correlated with the body mass index (r = 0.45, P = 0.01), homeostasis model assessment as a marker of insulin resistance (r = 0.53, P < 0.01), and systolic blood pressure (r = 0.37, P = 0.047), and tended to be correlated with low-density lipoprotein cholesterol, triglyceride, and CAVI. Olmesartan treatment resulted in a significant decrease in CAVI, serum A-FABP levels, and hsCRP, besides a significant reduction of blood pressure. Multiple regression analysis revealed that the change in CAVI was independently correlated with the change in serum A-FABP. Olmesartan ameliorated arterial stiffness in patients with hypertension, which may be involved in the reduction of serum A-FABP.